Back to search

National and Kapodistrian University of Athens

Μελέτη της επίδρασης του αναστολέα ρενίνης, αλισκιρένη, στα πρόδρομα ενδοθηλιακά κύτταρα σε ασθενείς με σακχαρώδη διαβήτη τύπου 2 και αρτηριακή υπέρταση

Abstract

dc:description

The aim of the present thesis was to investigate the effects of aliskiren on endothelial progenitor cells (EPCs), endothelial function and arterial stiffness in patients with type 2 diabetes and essential hypertension. The study enrolled type 2 diabetic patients aged >50 years, under stable glycaemic control and first diagnosed mild essential hypertension. The study included two phases. In phase A, twenty patients received aliskiren 150-300 mg/daily for 3 months. Only twelve of the twenty patients proceeded in phase B, in which hydrochlorothiazide (HCTZ) 12.5-25 mg/daily substituted for aliskiren for 3 more months. At baseline and at the end of each phase, we assessed i) EPCs of peripheral blood. EPCs were determined and counted by flow cytometry and culture of mononuclear cells of peripheral blood ii) brachial blood pressure (BBP), iii) central aortic systolic pressure (CSP), central aortic pulse pressure (CPP), aortic augmentation index (Aix) and pulse wave velocity (PWV) as markers of arterial stiffness, iv) brachial artery flow-mediated dilatation (FMD) as marker of endothelial function, v) left ventricular (LV) twisting and untwisting as markers of LV diastolic function vi) thiobarbituric reactive substances (TBARS) which indicate the levels of oxidative stress vii) total plasma nitrite / nitrate concentrations as markers of NO bioavailability and viii) the cardiovascular risk markers high-sensitivity C-reactive protein (hsCRP) and lipoprotein associated phospholipase A2 (Lp-PLA2) activity. Aliskiren similarly reduced BBP and CSP, increased FMD (p<0.001) and EPCs number (p<0.001), decreased PWV and Aix (p<0.05), and improved markers of LV function. Although substitution of HCTZ sustained BBP at similar levels, CSP, CPP and echocardiographic indices returned at baseline levels. Simultaneously, the improvement of FMD, PWV, Aix and EPCs number achieved by aliskiren was abolished after treatment with HCTZ. In conclusion, aliskiren had a favorable effect on EPCs, endothelial function, arterial stiffness and improved LV function. These effects were independent of BBP lowering, as they were not observed after the achievement of similar values of BBP with HCTZ.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mazioti, Maria
  • Μαζιώτη, Μαρία

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/41717

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mazioti, Maria; Μαζιώτη, Μαρία. Μελέτη της επίδρασης του αναστολέα ρενίνης, αλισκιρένη, στα πρόδρομα ενδοθηλιακά κύτταρα σε ασθενείς με σακχαρώδη διαβήτη τύπου 2 και αρτηριακή υπέρταση. National and Kapodistrian University of Athens, 2014. http://hdl.handle.net/10442/hedi/41717